Biosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Truxima rival at a 10% discount following FDA approval. Truxima – originally ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

A final approval is expected soon. Subject to approval, the rituximab biosimilar will further contribute to revenues. RDY also markets Hervycta (trastuzumab), a biosimilar of Roche’s Herceptin ...

Dr. Reddy’s launches drug-free migraine management device in Europe DRL_RI is being developed as a biosimilar of MabThera (Rituximab), a cluster of differentiation 20 (CD20) directed cytolytic ...

Rituximab, hyaluronidase human 1400mg/23400 Units, 1600mg/26800 Units; soln for SC inj; preservative-free. Give by SC inj into abdomen. Premedicate with an antihistamine and acetaminophen prior to ...

Rituxan (rituximab) is not safe to receive while pregnant or breastfeeding. Certain factors, including the risk of fetal harm, may determine whether you should receive Rituxan treatment during ...

To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), a China ...